{"id":390514,"date":"2018-12-21T00:00:00","date_gmt":"2018-12-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2018-biopharma-type-2-diabetes-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-05-06T11:22:59","modified_gmt":"2026-05-06T11:22:59","slug":"dlsfmd0004-2018-biopharma-type-2-diabetes-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2018-biopharma-type-2-diabetes-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The type 2 diabetes therapy market will steadily\u00a0expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the most rapid growth are the sodium\/glucose cotransporter 2 (<abbr title=\"sodium glucose cotransporter\">SGLT<\/abbr>\u00a02) inhibitors\u2014due to the cardiovascular (<abbr title=\"cardiovascular\">CV<\/abbr>) benefit demonstrated by Jardiance\u2014and the glucagon-like peptide 1 (<abbr title=\"glucagon-like peptide\">GLP<\/abbr>\u00a01) receptor agonists\u2014due to their efficacy, potential for weight loss, and the\u00a0<abbr title=\"cardiovascular\">CV<\/abbr>benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>Following Jardiance\u2019s positive\u00a0<abbr title=\"cardiovascular\">CV<\/abbr>\u00a0results, will\u00a0<abbr title=\"sodium glucose cotransporter\">SGLT<\/abbr>\u00a02 inhibitors surpass the dipeptidyl peptidase (<abbr title=\"dipeptidyl peptidase\">DPP<\/abbr>)\u00a0<abbr title=\"intravenous\">IV<\/abbr>\u00a0inhibitors as the most valuable oral drug class?<\/li>\n<li>Boosted by positive\u00a0<abbr title=\"cardiovascular\">CV<\/abbr>\u00a0data, will Victoza continue to lead the\u00a0<abbr title=\"glucagon-like peptide\">GLP<\/abbr>\u00a01 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?<\/li>\n<li>Will investments by the pharmaceutical industry in novel\u00a0<abbr title=\"fixed-dose combination\">FDC<\/abbr>s such as Xultophy and Soliqua reap rewards?<\/li>\n<li>What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390514","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390514\/revisions"}],"predecessor-version":[{"id":576665,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390514\/revisions\/576665"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}